1. Home
  2. COLL vs EFC Comparison

COLL vs EFC Comparison

Compare COLL & EFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

HOLD

Current Price

$45.76

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

EFC

Ellington Financial Inc.

HOLD

Current Price

$12.95

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
COLL
EFC
Founded
2002
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
2015
2010

Fundamental Metrics

Financial Performance
Metric
COLL
EFC
Price
$45.76
$12.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
6
Target Price
$51.17
$14.54
AVG Volume (30 Days)
406.2K
2.6M
Earning Date
02-26-2026
02-25-2026
Dividend Yield
N/A
12.06%
EPS Growth
N/A
1.22
EPS
1.63
1.33
Revenue
$757,067,000.00
$329,815,000.00
Revenue This Year
$26.17
N/A
Revenue Next Year
$3.65
$8.81
P/E Ratio
$28.17
$9.72
Revenue Growth
26.34
13.84
52 Week Low
$23.23
$11.12
52 Week High
$50.79
$14.40

Technical Indicators

Market Signals
Indicator
COLL
EFC
Relative Strength Index (RSI) 46.77 39.66
Support Level $43.99 $12.72
Resistance Level $49.31 $13.01
Average True Range (ATR) 1.62 0.26
MACD -0.12 -0.01
Stochastic Oscillator 38.19 50.66

Price Performance

Historical Comparison
COLL
EFC

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

About EFC Ellington Financial Inc.

Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. it acquires reverse mortgage loans both through its origination activities and through secondary market purchases.

Share on Social Networks: